The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...

The following is a summary of “High 11-ketotestosterone linked to shorter time to castration resistance in recurrent ...

The expansion in indications comes after the company’s Phase III trial saw the treatment extending survival in patients with ...

High-level results from the company’s ongoing CAPltello-281 phase 3 study demonstrated that a combination of Truqap, Johnson ...

Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.

Diet is increasingly seen as a modifiable risk factor in prostate cancer. Recent studies have shown that ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Monday positive high-level results from CAPItello-281 Phase III trial of ...